Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.810
+0.020 (1.12%)
At close: Mar 28, 2025, 4:00 PM
1.700
-0.110 (-6.07%)
Pre-market: Mar 31, 2025, 8:25 AM EDT
Zentalis Pharmaceuticals Employees
Zentalis Pharmaceuticals had 166 employees as of December 31, 2024. The number of employees increased by 42 or 33.87% compared to the previous year.
Employees
166
Change (1Y)
42
Growth (1Y)
33.87%
Revenue / Employee
$406,175
Profits / Employee
-$999,030
Market Cap
129.98M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ZNTL News
- 4 days ago - Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - GlobeNewsWire
- 5 days ago - Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 15 days ago - Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - GlobeNewsWire
- 27 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer - GlobeNewsWire